Azacitidine (5-Azacytidine)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza

39 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 127 In stock
EUR 95 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Azacitidine (5-Azacytidine) has been cited by 39 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  NVHCWnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fodlAvOS13MDFOwG0> MXSxNk04OiCq M4KzN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NVHPbHlLOjZzM{OyOFY>
Jurkat  NUHEXFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHwOVgxNjFvNUCg{txO MVGxNk04OiCq M{\jR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MkT5NlYyOzN{NE[=
CA46 NYnPTWI4TnWwY4Tpc44hSXO|YYm= NFrueI4zOMLiwsXN M1O2O|Q5KGh? NV\3Umh[cW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO|aX;u NY[yVXpGOjZzM{OyOFY>
Raji  MoHHSpVv[3Srb36gRZN{[Xl? NVq5NppnOTYEoNM1US=> NHy4TVQ1QCCq MUjpcoNz\WG|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25? M{HPd|I3OTN|MkS2
Jurkat  NVHXXYZCTnWwY4Tpc44hSXO|YYm= M2XhTVMvPcLiwsXN M3zpR|Q5KGh? M{\IeYlv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?= M2rHd|I3OTN|MkS2
MDA-MB-231 Mlv5SpVv[3Srb36gRZN{[Xl? MXexM|IvPS93IN88US=> MnyzOFghcA>? NGnGZZBl\WO{ZXHz[ZMhfGinIGDUVG4yOiCneIDy[ZN{cW:wIHH0JJRp\SClb37j[ZJvfHKjdHnvckBw\iB3wrFOwG0hPDkEoHi= M3jjXVI2QDF5MkK5
MDA-MB-231 MYjGeY5kfGmxbjDBd5NigQ>? MV6xM|IvPS93IN88US=> Mk\UOFghcA>? NH;kUodqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDFMYNi\GincnnuJI1TVkFiYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDJwNdMg{txO\m:{IES4xsBp MVGyOVgyPzJ{OR?=
MDA-MB-231 MYHGeY5kfGmxbjDBd5NigQ>? NUDTSZppOS9{LkWvOUDPxE1? NVm1XI9WOjRxNEigbC=> NIj1NoFqdmS3Y3XzJEB{cWewaX\pZ4FvfCCSQWLQJINt\WG4YXflJIFnfGW{IES4JIg> NVr6WpRjOjV6MUeyNlk>
MCF-7 MonISpVv[3Srb36gRZN{[Xl? NUm0OIZ5OS9{LkWvOUDPxE1? NIrYR3UzPC92ODDo MWXpcoNz\WG|ZYOgVGFTWCClbHXheoFo\cLi MUSyOVgyPzJ{OR?=
MDA-MB-231  MXLGeY5kfGmxbjDBd5NigQ>? MXGxM|IvPS93IN88US=> MmLLNlQwPDhiaB?= MYjpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gcYlTVkFvMUK0JIF1KHSqZTDjc45k\XKwdILheIlwdiCxZjC1JO69VQ>? NX:xd5NyOjV6MUeyNlk>
A498 NEDiOo9HfW6ldHnvckBCe3OjeR?= MoT0NVAhyrWP M{Ta[|czKGh? NIrMWmJqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> MWWyOVU3QTB6Nh?=
CaKI-2 NVTyUllNTnWwY4Tpc44hSXO|YYm= NWLFfpdSOTBiwsXN M4qxdlczKGh? NGfk[ZNqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> NYO3Z2pWOjV3NkmwPFY>
Ketr-3 NYTlTZFITnWwY4Tpc44hSXO|YYm= NHv3c2kyOCEEtV2= M{XC[|czKGh? MnXPbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u M2TWSlI2PTZ7MEi2
A253 NWLqd49MTnWwY4Tpc44hSXO|YYm= MmLXNVAhyrWP MYiwMVQh\A>? NHrVVIdqdmO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCuZY\lcEBw\iC2aHWgUVNTyqCjZoTldkAzPCCq NU\P[5lLOjV2OEW1N|Y>
A253 MoDUSpVv[3Srb36gRZN{[Xl? MXexNEDDvU1? MmrVO|IhcA>? MlvSbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIITo[UBOO1JiaX6gZo91cCCvZX3idoFv\SCjbnSgZ5l1d3OxbHnjJJBz\XCjcnH0bY9vew>? MWWyOVQ5PTV|Nh?=
A253 NYnDbpVDTnWwY4Tpc44hSXO|YYm= NHHiNWoyOCEEtV2= MYCwMVQh\A>? NI\nc4Zz\WS3Y3XzJJRp\SB3LX3leIh6dGO7dH;zbY5mKGOxboTlcpQ> NHnrNYozPTR6NUWzOi=>
PC3 MV\GeY5kfGmxbjDBd5NigQ>? MVKwMlIh|ryPwrC= MXq0JIQ> Mlf4bY5kemWjc3XzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiSVfGRnA4NCCVRmLQNUBidmRiU1zDOmEyPSClb33ibY5m\CC5aYToJGdUUzF{Nh?= NWfZdVA3OjV2N{ezOFA>
MCF7 MojESpVv[3Srb36gRZN{[Xl? M{LkUFAvOyEQvF5CpC=> NF3nc4g1KGR? NET1fFlqdmO{ZXHz[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDJS2ZDWDduIGPGVnAyKGGwZDDTUGM3STF3IHPvcYJqdmWmIIfpeIghT1ONMUK2 Mn3KNlU1Pzd|NEC=
PC3 NYTwTXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2wMlIh|ryPwrC= NWDaRm9uPCCm MWHk[YNz\WG|ZYOgeIhmKGOnbHyg[5Jwf3SqIITvJFIxNjNnIHPvcYJqdmWmIIfpeIghT1ONMUK2 M3vLPFI2PDd5M{Sw
MCF7 NHfqUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj2VJUxNjNizszNxsA> NEe3N4g1KGR? M3PEc4Rm[3KnYYPld{B1cGViY3XscEBoem:5dHigNlQvQCViY3;tZolv\WRid3n0bEBIW0tzMk[= NHrGZZczPTR5N{O0NC=>
BGC-823 MUXGeY5kfGmxbjDBd5NigQ>? NYPyTYVKPcLizszN M2rM[VczKGh? MoPO[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> NHzyTZozPTR5NUezNy=>
MKN28 NVvJPIROTnWwY4Tpc44hSXO|YYm= NVW4VFFjPcLizszN NULDV2ZWPzJiaB?= MX3k[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 NYi0codMOjV2N{W3N|M>
SGC-7901 MnXKSpVv[3Srb36gRZN{[Xl? MVe1xsDPxE1? MVG3NkBp NXGxXZNJ\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? M3LGd|I2PDd3N{Oz
MKN45 M{PrR2Z2dmO2aX;uJGF{e2G7 NXPpXno4PcLizszN NWPodIIzPzJiaB?= NELUOJBl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 NXXnTIhzOjV2N{W3N|M>
BGC-823 NX3RR3d[TnWwY4Tpc44hSXO|YYm= MkHMOeKh|ryP Mn;oO|IhcA>? Mn;S[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= NGTadVkzPTR5NUezNy=>
MKN28 NUDNWIdDTnWwY4Tpc44hSXO|YYm= NV[1XFA4PcLizszN M1LQTVczKGh? MmnY[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= Ml7aNlU1PzV5M{O=
SGC-7901 M2T6fGZ2dmO2aX;uJGF{e2G7 NYHTZ25XPcLizszN MU[3NkBp MYnk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 MUKyOVQ4PTd|Mx?=
MKN45 M3HVUWZ2dmO2aX;uJGF{e2G7 NGXTcIo2yqEQvF2= Mnj2O|IhcA>? MV7k[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 MlXZNlU1PzV5M{O=
HREC M1js[GZ2dmO2aX;uJGF{e2G7 M2T4T|UwOTEEoN88US=> MUe0PEBp NVn1e5hOcW6mdXPld{BRTUSIIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHLTNIkzPTN3Mke0Oy=>
HRPE M4SxVWZ2dmO2aX;uJGF{e2G7 MYe1M|ExyqEQvF2= NYnvNnpmPDhiaB?= MnSzbY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGruc4wzPTN3Mke0Oy=>
HREC NYLIXoE2TnWwY4Tpc44hSXO|YYm= NIDpOm82NzFywrFOwG0> MWm0PEBp Mlnz[I94di2{ZXf1cIF1\XNib3[gWmVITixiSVPBUU0yKCiwb4SgdJJwfGWrbjDs[ZZmdCCrbjDIVnBGKGOnbHzzLUwhUUxvMd8yJIRwe2VvZHXw[Y5l\W62bIm= NUe4R4hiOjV|NUK3OFc>
HRPE MlrjSpVv[3Srb36gRZN{[Xl? NWrWcGM6PS9zMNMg{txO NYLtOoFYPDhiaB?= MVnkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLTD2x{tItKGGwZDDNUXAzKGSxc3Wt[IVx\W6mZX70cJk> M3ywOlI2OzV{N{S3
MSCs NIjrPG9HfW6ldHnvckBCe3OjeR?= M{XmN|ExKM7:TR?= NIq1UG8zPCCq MmnJdJJwdW:2ZYOgeIhmKGOxbX3peI1mdnRib3[gUXNEeyC2bzDtfY9k[XKmaXHsJIRq\m[ncnXueIlifGmxbh?= NX7vdYdUOjV|NUGzPVU>
HL-60 M2DnNWZ2dmO2aX;uJGF{e2G7 M3WzOVUh|ryP M4\oVFczKGh? MmHaSG1UVw>? MlGxd4lodmmoaXPhcpRtgSC3cILl[5Vt[XSnczDaUmY{QDJiZYjwdoV{e2mxbh?= M{HyPVI2OzF7MES5
MV4-11 MYPGeY5kfGmxbjDBd5NigQ>? NYfrSJA4PSEQvF2= NEjCbYo4OiCq NXrtVFhJTE2VTx?= NYnr[XRLe2mpbnnmbYNidnSueTD1dJJm\3WuYYTld{BbVkZ|OEKg[ZhxemW|c3nvci=> M2XNNlI2OzF7MES5
A2780 MXrGeY5kfGmxbjDBd5NigQ>? Mo\1OUDDvU4EoB?= MoTxO{Bl NX7lZohVcW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?= NFvI[2ozPTJ7OU[5OC=>
CP70 NUnORXRwTnWwY4Tpc44hSXO|YYm= NFLJXng2KML3TdMg NFrqeGE4KGR? NH\XUJRqdmO{ZXHz[ZMhTE6DIH3leIh6dGG2aX;uJIxmfmWu MoPINlUzQTl4OUS=
A2780 MnrKSpVv[3Srb36gRZN{[Xl? Mn\wOUDDvU4EoB?= NWe1d5R4PyCm MX33[YFs\W6|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>? NYezXWNROjV{OUm2PVQ>
CP70 NWH0TW9OTnWwY4Tpc44hSXO|YYm= MYO1JOK2VcLi NGjUZ|c4KGR? NI[3XW14\WGtZX7zJJRp\SCuZY\lcEBw\iCvZYTofYxifGmxbh?= M1L4V|I2Ojl7Nkm0
OCM3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH2NXZHOC53L{GvNkDPxE1? MVS3JIQ> MnPGSG1UVw>? MoPtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M1u5V|I2OTR4OUix
92.1 NUnhSWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOwMlUwOS9{IN88US=> MkLFO{Bl M3GzO2ROW09? MlrhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M2XQTlI2OTR4OUix
OCM1 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLlcGFWOC53L{GvNkDPxE1? M4jBb|ch\A>? MV3EUXNQ NGLxSWlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MnrENlUyPDZ7OEG=
OMM1 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjLNE42NzFxMjFOwG0> M2LNRlch\A>? M2\odGROW09? M{T4PYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NVHzZZZYOjVzNE[5PFE>
Mel 285 M3Hu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DMeFAvPS9zL{Kg{txO M3f1Z|ch\A>? NHLNNGJFVVOR M{jse4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MY[yOVE1Pjl6MR?=
Mel 290 NXjyXWg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jD[lAvPS9zL{Kg{txO NEHiPYY4KGR? M1vyemROW09? MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3PpO|I2OTR4OUix
OCM3 M4TCbWZ2dmO2aX;uJGF{e2G7 M{fJdlAvPS9zIN88US=> MmjkOFghcA>? NFrGVIlFVVOR NFXiWW5l\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7 NX[0W4d6OjVzNE[5PFE>
92.1 MmPVSpVv[3Srb36gRZN{[Xl? MUKwMlUwOSEQvF2= NVf0R|JmPDhiaB?= Mnm2SG1UVw>? Mnrr[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NF3xe2kzPTF2Nkm4NS=>
OCM1 MYrGeY5kfGmxbjDBd5NigQ>? NH;xUlgxNjVxMTFOwG0> NWDmSolYPDhiaB?= NWfROIk5TE2VTx?= M{fneoRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? MWmyOVE1Pjl6MR?=
OMM1 M2\oVGZ2dmO2aX;uJGF{e2G7 M3L4OlAvPS9zIN88US=> MX[0PEBp NW\QdnN2TE2VTx?= NXHaPXNk\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= MXSyOVE1Pjl6MR?=
Mel 285 MoPrSpVv[3Srb36gRZN{[Xl? MXywMlUwOSEQvF2= MkW3OFghcA>? NHzkNI9FVVOR M3:5ToRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? M1rtXlI2OTR4OUix
Mel 290 NILtRXJHfW6ldHnvckBCe3OjeR?= NELtZVYxNjVxMTFOwG0> NX7qXpM3PDhiaB?= NHTROJNFVVOR NGHhblNl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7 NH;UV4UzPTF2Nkm4NS=>
OCM3 M4mwPWZ2dmO2aX;uJGF{e2G7 NHzk[G4xNjVxMTFOwG0> MoHXOFghcA>? MXHEUXNQ M2fWdIRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA> NWLZfIE2OjVzNE[5PFE>
Mel 290 M{f6bWZ2dmO2aX;uJGF{e2G7 NHHOe4wxNjVxMTFOwG0> Mn;TOFghcA>? M{XG[GROW09? NIDuNmJl\WO{ZXHz[ZMhcW64YYPpc44h\G:|ZTDk[ZBmdmSnboTsfeKh M3LUOVI2OTR4OUix
OMM1 MVzGeY5kfGmxbjDBd5NigQ>? NEG1WWYxNjVxMTFOwG0> M1\y[VQ5KGh? NEjze5RFVVOR NID2NFRl\WO{ZXHz[ZMhcW64YYPpc44h\G:|ZTDk[ZBmdmSnboTsfeKh M3\2VVI2OTR4OUix
OCM1 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MonzNE42NzFizszN MVy1JIQ> NUHhWWQ2TE2VTx?= M2jFRoRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u MWSyOVE1Pjl6MR?=
92.1 NYW0flc6S2WubDDWbYFjcWyrdImgRZN{[Xl? MoTDNE42NzFizszN M3\ybVUh\A>? MUTEUXNQ NW\v[ZBs\GWlcnXhd4V{KHKjZHnheIlwdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIlvcGmkaYTpc44> Mlv5NlUyPDZ7OEG=
OCM1 MlnVSpVv[3Srb36gRZN{[Xl? M1L5UlAvPS9zIN88US=> NVfw[3NLPDhiaB?= NIfQTXhFVVOR NFPLe4Vk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp MmXRNlUyPDZ7OEG=
OCM3 M3j3PGZ2dmO2aX;uJGF{e2G7 Ml\mNE42NzFizszN M2f4blQ5KGh? NXnTdJhqTE2VTx?= NE\TVopk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp NHT6cYgzPTF2Nkm4NS=>
92.1 MYLGeY5kfGmxbjDBd5NigQ>? Mlu2NE42NzFizszN MV[0PEBp NXG1NJozTE2VTx?= MnjWZ4F2e2W|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?= NEK2N|EzPTF2Nkm4NS=>
IMR32 NGnlZ5ZHfW6ldHnvckBCe3OjeR?= MlP4N{DPxE1? Mni3O|IhcA>? M2rrW2ROW09? NYT4ZohicW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 NW\BZmJIOjVzMES4OVA>
IMR5-75 NED6R4JHfW6ldHnvckBCe3OjeR?= NF\jTpA{KM7:TR?= NFPOcG44OiCq NYXDXGc4TE2VTx?= MoDzbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 MlTNNlUyODR6NUC=
Be(2)-C M1:1UmZ2dmO2aX;uJGF{e2G7 M164eFMh|ryP MlLIO|IhcA>? M3rabmROW09? MXXpcoR2[2W|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= NGnTPXIzPTFyNEi1NC=>
Bxpc-3 NXvoSnhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvjOU8yOCEQvF2= MWmyOE81QC95MjDo MnjobY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhSniyYz2zJINmdGy|IHnuJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XK| M3LyVVI2ODZzN{Ox
Bxpc-3 MWPBdI9xfG:|aYOgRZN{[Xl? NUPseVVzPS9zMDFOwG0> NHjG[nMzPC92OD:3NkBp MkOybY5lfWOnczDhdI9xfG:|aYOgbY4hfGmvZT2gZY5lKGOxbnPldo51emG2aX;uJI1idm6ncoO= M32zVVI2ODZzN{Ox
Bxpc-3 MlnNSpVv[3Srb36gRZN{[Xl? MU[1M|ExKM7:TR?= NVfuPGRWOjRxNEivO|IhcA>? NXXrWJhN\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo NF\O[2szPTB4MUezNS=>
Bxpc-3 MnKySpVv[3Srb36gRZN{[Xl? MlvzOU8yOCEQvF2= NXPlbJNYOjRxNEivO|IhcA>? MUfk[YNz\WG|ZYOgZ5lkdGmwREGg[ZhxemW|c3nvckBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gNVAh|ryP NUjiVVQ2OjVyNkG3N|E>
Bxpc-3 NViydFNSTnWwY4Tpc44hSXO|YYm= MVy1M|ExKM7:TR?= NX\LXVJ2OjRxNEivO|IhcA>? Mnjm[I94di2{ZXf1cIF1\VNiYz3tfYMhdVKQQTDlfJBz\XO|aX;uJIlvKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYLz MXeyOVA3OTd|MR?=
HL-60 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zOfFEvOCEQvF2= MYG0PEBp M{nVTZNq\26rZnnjZY51dHliaX7obYJqfHNiSFytOlAh[2WubDDndo94fGkEoB?= NEXxTlgzPTB3MUGxPS=>
HL-60 MWjGeY5kfGmxbjDBd5NigQ>? NWTEbWNrOS5yIN88US=> Mme3OFghcA>? NH;oRoVqdmO{ZXHz[ZMheDJzV1HGNU9EUVBzwrDhcoQh[2G|cHHz[U0{KGW6cILld5Nqd28EoB?= NYXMZ|Z4OjVyNUGxNVk>
HL-60 Mki1SpVv[3Srb36gRZN{[Xl? NXmwTXN6OS5yIN88US=> MWS0PEBp NHrKOZRl\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= MUOyOVA2OTFzOR?=
HuTu-80  NF36ZXlHfW6ldHnvckBCe3OjeR?= M4TaXlEwPS9zMDFOwG0> Mn\GOFgwPzJiaB?= NXvKdIxucW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGi3bXHuJG5RSzGOMTDtVm5CKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NETUfGQzPDlyNEC2Ni=>
Caco2  NH;YfJhHfW6ldHnvckBCe3OjeR?= NE\UN3YyOCEQvF2= NGLQOJo1QCCq NWPwR3lxcW6lcnXhd4V{KE6SQ{HMNUBmgHC{ZYPzbY9v NILafZEzPDlyNEC2Ni=>
HepG2  MlXQSpVv[3Srb36gRZN{[Xl? MknHNE0zPSEQvF2= MnPhNlQhcA>? M4XU[4Rm[3KnYYPld{B{fWK2aXzpd4lvN2uneHnuJJR6eGViOTCoVGNUUzlrIIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJk> NFv1eGszPDh3NU[0Oi=>
HepG2  MmXNSpVv[3Srb36gRZN{[Xl? Mke3NE0zPSEQvF2= NFLQTGgzPCCq M4D5RYlv[3KnYYPld{Btd3diZHXud4l1gSCuaYDvdJJwfGWrbjDy[YNmeHSxcjCoUGRNWiliZ3Xu[UBmgHC{ZYPzbY9vyqB? MkLMNlQ5PTV4NE[=
HepG2  NUC1NYY1TnWwY4Tpc44hSXO|YYm= NXm4XJRrOTBizsztxsA> MV[wMVI1KGh? NYTiNFRm\GWlcnXhd4V{yqCSQ2PLPeKh[W6mwrDIUWdEWsLiZYjwdoV{e2mxbjDhcoQhcW6lcnXhd4V{KEyGTGKg[ZhxemW|c3nvckBi\nSncjC2JIg> M4nYXFI1QDV3NkS2
HepG2  NVXkSodJTnWwY4Tpc44hSXO|YYm= NUe3VpBWOTBizszt M2LvO|I1KGh? MUTwdo9ud3SnczDjfZRwe2:uaXOgcoV2fHKjbDDsbZBq\CCjY3P1cZVt[XSrb36gbY5l\XCnbnTlcpRtgSCxZjDlfI9o\W6xdYOgcIlxd3C{b4TlbY5{ NGXTVXIzPDh3NU[0Oi=>
HepG2  MXzGeY5kfGmxbjDBd5NigQ>? Mn\KNVAh|ryv M3r6O|I1KGh? MnjodJJmfmWwdIOgV3JGSlBicILvZ4V{e2mwZx?= MXqyOFg2PTZ2Nh?=
HC45  M4\xPWZ2dmO2aX;uJGF{e2G7 MVK1xtVOyqB? MUG0JIQ> MUjy[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? M3TxXlI1PzZ{OEC5
CNDT2  NVXMXoVUTnWwY4Tpc44hSXO|YYm= NF\V[I42yrWPwrC= MkPZOEBl NHTSR3Jz\WS3Y3XzJJRp\SCvZYTofYxifGmxbjDs[ZZmdHNib3[gW2lHOSxiUEG2MEBEYEOOMUSsJG5MYDMkgKOzMEBETEhzLDDMRW1COSxiYX7kJGNVVk6EMR?= NXewcXNCOjR5NkK4NFk>
CNDT2  NEDU[WtHfW6ldHnvckBCe3OjeR?= MWK1xtVOyqB? NF;mTVQ1KGR? NHnrWlZqdmO{ZXHz[ZMh\2WwZTDlfJBz\XO|aX;uJI9nyqCZSV[xMEBROTZuIFPETFEtyqCOQV3BNUzDqGGwZNMgR3RPVkJz MYCyOFc3OjhyOR?=
T-cells NVz1UpFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\xOU8zOCEQvF2= NITrbXMxNTR6IHi= NGr0[3hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MnTDNlQ4PTd{OEO=
CD3+ T-cells NWWy[XZiTnWwY4Tpc44hSXO|YYm= M3vxeVUwOjBizszN Ml7vOFghcA>? M{SxNJVxemWpdXzheIV{KHBzNTDlfJBz\XO|aX;u NV3XcGgxOjR5NUeyPFM>
CD4+ T-cells M4LJN2Z2dmO2aX;uJGF{e2G7 MUG1M|IxKM7:TR?= NFjXRZE1QCCq MVz1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= M4O5eFI1PzV5Mkiz
CD8+ T-cells MXfGeY5kfGmxbjDBd5NigQ>? MV21M|IxKM7:TR?= M3j6cFQ5KGh? MVX1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= NWPEWHViOjR5NUeyPFM>
CD3+ T-cells NGnXT5BHfW6ldHnvckBCe3OjeR?= NWPxSohXPS9{MDFOwG0> NVT5N3U{PDhiaB?= MlvOeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhTk:[UEO= NYLM[YhLOjR5NUeyPFM>
CD4+ T-cells NEnBdFNHfW6ldHnvckBCe3OjeR?= NVrhUFA2PS9{MDFOwG0> MnvvOFghcA>? MofWeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhTk:[UEO= MmPqNlQ4PTd{OEO=
CD4+ T-cells M1\oTmZ2dmO2aX;uJGF{e2G7 Mn3JOU8zOCEQvF2= NVLyU2lrPDhiaB?= MlzsdoVlfWOnczDURmVVOcLibWLORUBmgHC{ZYPzbY9v NFTFXmUzPDd3N{K4Ny=>
CD4+ T-cells MXvGeY5kfGmxbjDBd5NigQ>? MUm1M|IxKM7:TR?= MVi0PEBp MWH1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[uKhWk:UzsP0xsA> MkXhNlQ4PTd{OEO=
CD4+ T-cells MmX0SpVv[3Srb36gRZN{[Xl? MomyOU8zOCEQvF2= NUPIXVcyPDhiaB?= MorjbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? NFL5bmYzPDd3N{K4Ny=>
CD8+ T-cells MWTGeY5kfGmxbjDBd5NigQ>? MnrZOU8zOCEQvF2= M4TjWFQ5KGh? MortbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? NF7NR2QzPDd3N{K4Ny=>
CD3+ T-cells NVKzZmg4TnWwY4Tpc44hSXO|YYm= NGHjTY82KM7:TR?= MXS0PEBp MYDy[YR2[2W|IHzvcocufGW{bTDt[Y1wenliY3XscEBxcGWwb4T5dIU> NWrKNYY{OjR5NUeyPFM>
U937 NXPwd241SXCxcITvd4l{KEG|c3H5 MoHUNVAh|ryP M4LJNVczKGh? MmH2bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NH3jNZAzPDZ6MEi2OS=>
HL-60 NILZUXVCeG:ydH;zbZMhSXO|YYm= MnGzNVAh|ryP MXi3NkBp M3GzXYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NGXWNGgzPDZ6MEi2OS=>
MCF7 NGn2NYVHfW6ldHnvckBCe3OjeR?= M3T2XVUh|ryP MkHrOFghcMLi MX\kbZNxdGG7czDz[Yxm[3SrdnWgeI95cWOrdImgeI94[XKmIIP1d5BmdmSnZDDNR2YuPyClZXzsdy=> MWGyOFY{OzN3MB?=
MCF7 NF\HUZNHfW6ldHnvckBCe3OjeR?= NULSb2V6OTBizszN MkLPNlQhcMLi Mnf0bY5lfWOnczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\SB5IHHu[EBRSVKSwrC= NX3lXWkzOjR4M{OzOVA>
MCF7 NUHUVo4zTnWwY4Tpc44hSXO|YYm= NHv3NoEx6oDVMD61JO69VcLi NXLTNlh2PyCm MXzpcohq[mm2czD0bIUh\3Kxd4ToJG1ETi15IIT1cY9ze3CqZYLld{BqdiC|dYPw[Y5{cW:wIHP1cJR2emW|wrC= NUPPN|RbOjR4M{OzOVA>
MCF7 M2PMRWZ2dmO2aX;uJGF{e2G7 M4LkOlAvPSEQvF5CpC=> MU[xOEBl NU\aPJBqemWmdXPld{B1cGVic3n6[UBw\iCPQ1[tO{Bkd2yxbnnld{BmdWKnZHTl[EBqdiC|b3\0JIFo[XJ? NE\v[Y0zPDZ|M{O1NC=>
MCF7 MmTmSpVv[3Srb36gRZN{[Xl? NIrkUncxNjB34pETNlAh|ryP NEnjcmwyKGR? M1\nNJJm\HWlZYOgeIhmKGOub37hcEB{fXK4aY\hcEBw\iCPQ1[tO{Bk\WyuczDpckBud26xbHH5[ZIh[3WudIXy[ZM> MnO5NlQ3OzN|NUC=
T47D  MmXOSpVv[3Srb36gRZN{[Xl? NWTCS2Q4OC53IN88US=> NI\kXpo1KGR? MkjKbY5pcWKrdIOgeJVud3K|cHjldoUh\m:{bXH0bY9v MWSyOFY{OzN3MB?=
MCF7 NVHZWnBtTnWwY4Tpc44hSXO|YYm= Mon5NE426oDVMUCg{txO MYK0PEBpyqB? NYLFSFdYcW6qaXLpeJMhfGinIHfhdEBkdG:|dYLlJIlvKHSqZTD3c5Vv\CCqZXHsbY5oKGG|c3H5 M2rlNVI1PjN|M{Ww
MCF7 NIjLOIlHfW6ldHnvckBCe3OjeR?= MXSwM|ExKM7:TR?= Mlr2NlQhcA>? NUn5WGhQcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWDl? MVuyOFY{OzN3MB?=
MDA-MB-231  NIXEXYRHfW6ldHnvckBCe3OjeR?= MlvuNE426oDVMUCg{txO M33FZVM3KGh? NXviWm9KcW6qaXLpeJMhfGinIH3p[5JifGmxbh?= NI\qeFMzPDZ|M{O1NC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 ; 

PubMed: 28210112     


AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control.

c-PARP / p-H2AX / H2AX; 

PubMed: 28210112     


AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘

28210112
Immunofluorescence
HMGB1 ; 

PubMed: 29097772     


U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemセ᎒

29097772
Growth inhibition assay
Cell viability ; 

PubMed: 28210112     


AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖

28210112
In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
- Collapse
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
in solvent
Synonyms 5-AzaC,Ladakamycin, AZA,5-Aza
Smiles C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04172844 Recruiting Drug: Azacitidine|Drug: Venetoclax|Drug: Pevonedistat Acute Myelogenous Leukemia Ehab L Atallah|Medical College of Wisconsin January 13 2020 Phase 1
NCT04214860 Recruiting Drug: APR-246|Drug: Venetoclax|Drug: Azacitidine Myeloid Malignancy Aprea Therapeutics December 13 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) supplier | purchase Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) cost | Azacitidine (5-Azacytidine) manufacturer | order Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID